The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Harnessing Genomics in the Rare Diseases Realm

Harnessing Genomics in the Rare Diseases Realm

March 12, 2020 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Interpretation of Data

Dr. LEE

Dr. Lee

Brendan Lee, MD, PhD, chair of molecular and human genetics at Baylor College of Medicine, Houston, said it’s true that the cost of genome and exome sequencing has plummeted, but that is just one part of the problem.

You Might Also Like
  • Fibrotic Diseases of the Retroperitoneum & Skin, & Rare Scleroderma Mimics
  • Opinion: Rheumatologists Cautioned Against Wasteful Testing to Find Rare Diseases
  • Rheumatologist John P. Atkinson, MD, Continues Research into Rare Diseases
Explore This Issue
March 2020
Also By This Author
  • Racial Disparity in RA & OA: ACR Convergence 2020 Preview

“The cost of sequencing is dropping enormously, but it is ultimately the interpretation of that sequence which is the challenge,” he said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The results of whole exome sequencing are often not straightforward, pointing to a single diagnosis, Dr. Lee said. A study by a colleague at his center on whole exome sequencing (WES) of adults found that WES yielded a diagnosis rate of 17.5%, with a “dual” diagnosis involving “blended phenotypes” 7.1% of the time.3

Interpretation of WES data changes over time as new discoveries are made.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

At Dr. Lee’s center, the diagnostic yield of WES at one time point was 25% in one cohort of 250, and at a later time point it was 36%. In a larger cohort of 2,000, the yield rose from 25% to 30% when re-analyzed later, he said.4,5

“This is why, in fact, our lab tries in a structural fashion to integrate re-analysis in our pipeline so that when one orders a test, there is … an interval subsequently when there will be a re-analysis,” Dr. Lee said. “And this is not an easy task given the nature of genomic interpretation.”

Exome sequencing of infants in intensive care produced a diagnosis 36.7% of the time, and in 52% of those cases the diagnosis affected medical care, either by redirection of care, referral of a subspecialist or in diet or medication.6

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The bottom line question, Dr. Lee said, is how do we functionalize the genome?

He works with the Undiagnosed Diseases Network, in which patients apply and, if accepted, are seen at one of 12 regional U.S. sites. About 40% of patients are accepted for evaluation, and the diagnostic yield is 35%—even though many of the patients had exome sequencing done previously.

Dr. Lee said the Undiagnosed Diseases Network is not just out to make new diagnoses. It’s “also a laboratory in thinking about how this can be implemented more broadly.”

Challenges of Individualized Genomic Medicine

The promise is enormous, he said, but real challenges stand in the way of perfecting individualized genomic medicine. One is the knowledge itself, he said. “The knowledge base is evolving, and therefore this changes our interpretation.”

As individualization increases, the evidence base for it is bound to shrink, Dr. Lee said. “Sometimes there’s an inverse correlation with individualization and personalized medicine and what we view as evidence.”

“There are payer issues. And transformation of data into information requires the education of physicians and direct counseling of patients. And then there’s, of course, the regulatory oversight aspect.”

Pages: 1 2 3 | Single Page

Filed Under: 2019 ACR/ARP Annual Meeting, Conditions, Technology Tagged With: genomics, Precision MedicineIssue: March 2020

You Might Also Like:
  • Fibrotic Diseases of the Retroperitoneum & Skin, & Rare Scleroderma Mimics
  • Opinion: Rheumatologists Cautioned Against Wasteful Testing to Find Rare Diseases
  • Rheumatologist John P. Atkinson, MD, Continues Research into Rare Diseases
  • Genomics Research Highlighted at Lupus Conference

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.